Abstract
Warts are common benign skin tumors caused by human papilloma viruses. Recalcitrant facial warts tend to be cosmetically embarrassing to patients and difficult to treat for doctors. Recently, intralesional immunotherapy by antigens like Bacille Calmette–Guerin vaccine, candida antigen, and measles, mumps, and rubella (MMR) vaccine has shown promising efficacy. Here, we report two cases of Omani men who presented with recalcitrant facial warts that resolved completely with a single intralesional injection of the MMR vaccine.
Keywords
Publication details
- DOI
- 10.5001/omj.2022.01
- Journal
- Oman Medical Journal
- Publisher
- Oman Medical Specialty Board
- Open access
- Gold open access
Cite this article
APA 7
Al-Qassabi, A. M., & Al Kindi, A. (2022). Intralesional Immunotherapy with Measles-Mumps-Rubella Vaccine for Recalcitrant Facial Warts: A Report of Two Cases. Oman Medical Journal. https://doi.org/10.5001/omj.2022.01
MLA 9
Al-Qassabi, Al Mutasim, and Abdulrahman Al Kindi. "Intralesional Immunotherapy with Measles-Mumps-Rubella Vaccine for Recalcitrant Facial Warts: A Report of Two Cases." Oman Medical Journal, 2022. https://doi.org/10.5001/omj.2022.01.
Chicago (author–date)
Al-Qassabi, Al Mutasim, and Abdulrahman Al Kindi. 2022. "Intralesional Immunotherapy with Measles-Mumps-Rubella Vaccine for Recalcitrant Facial Warts: A Report of Two Cases." Oman Medical Journal. https://doi.org/10.5001/omj.2022.01.
Harvard
Al-Qassabi, A. M. and Al Kindi, A. (2022) 'Intralesional Immunotherapy with Measles-Mumps-Rubella Vaccine for Recalcitrant Facial Warts: A Report of Two Cases', Oman Medical Journal. doi:10.5001/omj.2022.01.
Vancouver
Al-Qassabi AM, Al Kindi A. Intralesional Immunotherapy with Measles-Mumps-Rubella Vaccine for Recalcitrant Facial Warts: A Report of Two Cases. Oman Medical Journal. 2022. doi:10.5001/omj.2022.01
IEEE
A. M. Al-Qassabi, and A. Al Kindi, "Intralesional Immunotherapy with Measles-Mumps-Rubella Vaccine for Recalcitrant Facial Warts: A Report of Two Cases," Oman Medical Journal, 2022, doi: 10.5001/omj.2022.01.